We make no valuation changes in the light of today"s news that the EPO announced it intends to grant Respiratorius the patent application for the RESP9000 series. This patent is commercially important for the project as it protects the asset until 2039 in Europe. We reiterate our Base case of SEK 2.8.

Länk till analysen